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Introduction
Long-term antipsychotic treatment of schizophrenia is associated
with the emergence of tardive dyskinesia (TD), a motor syndrome
consisting of involuntary and hyperkinetic movements [1].
Pathogenesis of this drug-induced movement disorder is not yet fully
established, but may be connected to oxidative stress-related indirect
pathway neurotoxicity [2]. Dysregulations in immune, hormonal and
neurotrophic systems have been postulated to be one of the
mechanisms underlying this form of neurotoxicity [3, 4]. Principle
aims of translational psychiatric research are searching for biomarkers
which can be used to diagnose pathological biochemical processes
and to identify molecular targets for treatment as well as development
of pharmacogenetic approaches to personalize this therapy.
Aims
The aim is to study potential endocrine, neurotrophic and
immunological markers of tardive dyskinesia in the blood serum of
patients with schizophrenia with antipsychotic therapy.
Methods
After obtaining approval of the study protocol by the local ethical
committee, suitable participants were recruited from psychiatric
hospitals. All subjects gave informed consent after proper explanation
of the study. TD was assessed cross-sectionally by the use of the
Abnormal Involuntary Movement Scale (AIMS) [1, 5]. The
concentrations of cortisol, brain-derived neurotrophic factor (BDNF),
prolactin, cytokines (tumor necrosis factor (TNFa), interleukin 1 (IL-
1β), interleukin 3 (IL-3), interleukin 6 (IL-6), interferon gamma (INF-
γ) and S100β were measured in blood serum using the
MILLIPLEX® MAP panels (Merck, Darmstadt, Germany) by the
multiplex analyzer MAGPIX (Luminex, USA). Statistical analyses were
performed using SPSS software for Windows. Results were expressed
as median and quartile intervals (Me [Q1; Q3]) or mean and standard
deviation (M±SD). Differences were considered significant at p≤0.05.
Results
In total 180 patients with schizophrenia, 128 males and 52 females (age
39.2±12.1 years), receiving long-term antipsychotic treatment were
included. These patients were divided into two groups: 71 patients
with tardive dyskinesia and 109 patients without this movement
disorder. A significant (p=0.04) decrease in BDNF concentration was
observed in patients with TD (1.9 [1.01; 2.99] ng/ml) in comparison to
patients without TD (2.66 [1.29; 3.89] ng/ml) (Fig.1). An increase
(p=0.05) of the serum IL-6 level of patients with TD (5.69 [3.55; 7.4]
pg/ml) was detected relative to patients without TD (4.69 [2.82; 6.13]
pg/ml) (Fig.2). In addition, a statistical trend (p=0.06) of increased
serum S100β concentration was found in TD patients (85.29±5.53
ng/L) compared to patients without this side effect (75.14±2.81 ng/L)
(Fig.3). No other significant differences were established concerning
the other assayed biomarkers.
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Discussion
The biological processes that might play a role in the
development of TD are not confined to the human brain per se.
Hormonal and immune systems are also involved, which may be
related to these systems being closely interrelated. Furthermore,
these parameters may provide information about risk factors of
the movement disorder. Identifying markers that can be used as
diagnostics or predictors of treatment response in people with
tardive dyskinesia will be an important step towards being able to
provide personalized treatment.
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Fig.1. Concentration of 
BDNF in the blood serum 
of patients with 
schizophrenia (Me [Q1; 
Q3]).
Fig.2. Concentration of IL-
6 in the blood serum of 
patients with 
schizophrenia (Me [Q1; 
Q3]).
Fig.3. Concentration of 
S100β in the blood serum 
of patients with 
schizophrenia (M±SD).
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